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Devices Versus Pharmacological Agents for
Stroke Prevention in Atrial FibrillationWe thank Drs. Messori and Trippoli for their com-
ments on our paper (1). They importantly highlight
the issue that the only 2 randomized trials in the
ﬁeld of left atrial appendage occlusion used warfarin
as the control value. Both randomized trials, PRO-
TECT AF (WATCHMAN Left Atrial Appendage System
for Embolic PROTECTion in Patients With Atrial
Fibrillation) (2) and PREVAIL (Watchman LAA
Closure Device in Patients With Atrial Fibrillation
Versus Long Term Warfarin Therapy) (3), compared
the Watchman device (Boston Scientiﬁc, Marl-
borough, Massachusetts) versus a control arm of
warfarin. The PROTECT AF trial had been planned
when warfarin was the most commonly used anti-
coagulant agent. Subsequently, several novel oral
anticoagulant agent (NOACS) have now been tested
versus warfarin for stroke prevention in the setting
of nonvalvular atrial ﬁbrillation.
Important questions remain, including what
would be the result of a randomized trial of
Watchman versus any one of the NOACS? No ran-
domized trial is available. Messori et al. (4) have
advanced the ﬁeld using an indirect comparisonapproach on the basis of a speciﬁc noninferiority
margin that had been used in other randomized trials
in the ﬁeld of NOACs versus warfarin. Initially pub-
lished in 2013, they have updated data in this current
letter (Figure 1 of Holmes Jr. [1]). In this indirect
comparison analysis, the “effectiveness of Watchman
fully satisﬁes the noninferiority criteria” of device
versus NOAC and even suggests superiority.
These ﬁndings are very important, interesting, and
exciting. We agree, however, with Dr. Messori and
colleagues that these “indirect analysis are largely
speculative”; they need to be replicated in more
robust scientiﬁc studies. This analysis, however, does
offer the potential that the role of left atrial
appendage occlusion devices will increase even in the
face of availability of new anticoagulant regimens.*David R. Holmes, Jr., MD
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